Clinical Trial Update: CapTemY90 for Grade 2/3 NET Liver Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CapTemY90 for liver metastases from neuroendocrine tumors (Grade 2) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• CapTemY90

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors | Phase 2 | Status: RECRUITING